Literature DB >> 32016072

Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?

Arpit Rao1, Emmanuel S Antonarakis2.   

Abstract

Entities:  

Year:  2019        PMID： 32016072      PMCID： PMC6976453          DOI： 10.21037/atm.2019.09.92

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

1.  Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.

Authors:  Fangfang Qu; Wanling Xie; Mari Nakabayashi; Haitao Zhang; Seong Ho Jeong; Xiaodong Wang; Kazumasa Komura; Christopher J Sweeney; Oliver Sartor; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  Clin Cancer Res       Date:  2016-08-03       Impact factor: 12.531

2.  AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.

Authors:  Anna Katharina Seitz; Silvia Thoene; Andreas Bietenbeck; Roman Nawroth; Robert Tauber; Mark Thalgott; Sebastian Schmid; Ramona Secci; Margitta Retz; Jürgen E Gschwend; Jürgen Ruland; Christof Winter; Matthias M Heck
Journal:  Eur Urol       Date:  2017-08-14       Impact factor: 20.096

Review 3.  Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?

Authors:  Arpit Rao; Neha Vapiwala; Edward M Schaeffer; Charles J Ryan
Journal:  Am Soc Clin Oncol Educ Book       Date:  2019-05-17

4.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

5.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.

Authors:  Scott M Dehm; Lucy J Schmidt; Hannelore V Heemers; Robert L Vessella; Donald J Tindall
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

6.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

Authors:  Rong Hu; Thomas A Dunn; Shuanzeng Wei; Sumit Isharwal; Robert W Veltri; Elizabeth Humphreys; Misop Han; Alan W Partin; Robert L Vessella; William B Isaacs; G Steven Bova; Jun Luo
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

7.  AR-V7 and treatment selection in advanced prostate cancer: are we there yet?

Authors:  Diogo A Bastos; Emmanuel S Antonarakis
Journal:  Precis Cancer Med       Date:  2018-09-18

8.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

9.  Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization.

Authors:  Shannon L Werner; Ryon P Graf; Mark Landers; David T Valenta; Matthew Schroeder; Stephanie B Greene; Natalee Bales; Ryan Dittamore; Dena Marrinucci
Journal:  J Circ Biomark       Date:  2015-05-05

10.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

Authors:  Howard I Scher; David Lu; Nicole A Schreiber; Jessica Louw; Ryon P Graf; Hebert A Vargas; Ann Johnson; Adam Jendrisak; Richard Bambury; Daniel Danila; Brigit McLaughlin; Justin Wahl; Stephanie B Greene; Glenn Heller; Dena Marrinucci; Martin Fleisher; Ryan Dittamore
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.